News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News 7 Experiences in Budapest this Summer You Won’t Find in Every Guidebook News reAlpha Enhances Mortgage Operations with AI-Powered Loan Officer Assistant News Mercury Selected to Improve U.S. Defense Supply Chain Resilience for Priority Domestic Microelectronics Technology News TSplus Joins the First Sino-French Economic Meetings in Amiens News Telnyx launches RCS Business Messaging for branded, interactive customer engagement News Joveo Recognized as Strategic Challenger in the 2025 Fosway 9-Grid™ for Talent Acquisition
